OP0016 Development of a panel of five miRNAs as a diagnostic tool for non-small-cell lung cancer
chunni zhang,cheng wang,meng ding,mingde xia,sidi chen,anh van le,rafael sotogil,yi shen,junjun wang,nan wang,wanjian gu,xiangdong wang,yanni zhang,ke zen,xi chen
DOI: https://doi.org/10.1016/j.ejca.2015.06.017
IF: 10.002
2015-01-01
European Journal of Cancer
Abstract:Background Circulating miRNAs have been recognised as stable markers for cancer detection. However, multiethnic, double-blind studies of non-small-cell lung cancer (NSCLC) are lacking. We aimed to identify a panel of serum miRNAs capable of accurately diagnosing NSCLC in ethnically diverse patients. Methods We randomly assigned 438 participants from both China and America, including 221 NSCLC patients, 160 normal controls, and 57 benign nodules. An initial miRNA screening was done on two pooled serum samples respectively from NSCLC and normal controls from a Chinese cohort using the TaqMan Low-Density Array. Candidate miRNAs from the screen were validated by qRT-PCR analysis in two additional Chinese cohorts. Risk score analysis was done to evaluate the diagnostic value of the selected miRNAs. Finally, we did a double-blind trial on 212 samples from an American cohort to validate our findings. Findings In both the training and validation sets, qRT-PCR analysis confirmed that miR-483-5p, miR-193a-3p, miR-25, miR-214, and miR-7 were significantly increased in Chinese patients with NSCLC compared with those in normal controls. The AUCs of the ROC curve of this five serum miRNA panel were 0.976 and 0.823 for the two confirmation sets, respectively. Furthermore, in a double-blind trial, the miRNA panel correctly classified 95% NSCLC cases and 84% normal and benign nodules controls. In addition, the panel was capable of distinguishing NSCLC from benign nodules with an AUC of 0.979 and sensitivity and specificity of 95% in the American cohort. The panel allowed correct prediction of 11 of 13 (85%) stage I–II tumours in Chinese cohorts and 55 of 58 (95%) stage I–II tumours in American cohort. Interpretation A panel of five serum miRNAs holds potential for accurate diagnosis of NSCLC in patients of different ethnicity.